BioCentury
ARTICLE | Clinical News

NeuTrexin trimetrexate glucuronate: Phase III data; marketed to treat Pneumocystis carinii pneumonia

May 24, 1999 7:00 AM UTC

Interim results from UBS's European Phase III trial showed a median survival time of 12.9 months for patients receiving NeuTrexin, 5-FU and leucovorin versus 10.1 months for those on 5-FU plus leucovorin. Data were presented at the American Society of Clinical Oncology meeting in Atlanta. ...